DexCom price target raised to $100 from $90 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $100 from $90 and keeps an Overweight rating on the shares. The firm notes the company reported full Q4 results, which were, overall, mixed. However, the company reiterated its 2025 financial guidance, with a commitment to deliver record domestic new patient additions. This is an area of concern among investors but the commentary should allay some of these fears, Piper adds.